Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter prospective study to assess the efficacy and safety of ZOMETA® in treatment of high-level NTX non small cell lung cancer with bone metastasis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborator: Novartis
• Treatments: Zoledronic Acid

Criteria

Inclusion Criteria:

• Age > 18

• Histologically confirmed non-small cell cancer

• One bone metastasis at least confirmed by image(X ray, CT or others)

• NTX > 50nM BCE/mM creatinine

• Life expectancy > 6 M

• ECOG <= 2

• Signed ICF

Exclusion Criteria:

• Women who are pregnant or in lactation

• Patients with hyperostosis with brain metastasis(exception of those without symptom or with Metastasis Lesions under controlled

• Previous or current treatment with any other bisphosphonates, bone- protecting, cytotoxic or targeted therapy

• Severe co-morbidity of any type that may interfere with assessment of the patient for the study -